Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
NRSN
$0.84
$
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Next Earnings
2026-02-25
Beta
1.607
Average Volume
Market Cap
Last Dividend
CIK
0001875091
ISIN
IL0011809592
CUSIP
M74240108
CEO
Alon Ben-Noon
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
17
IPO Date
2021-12-09
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell? | Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) traded down 14.7% during trading on Wednesday. The stock traded as low as $0.8531 and last traded at $0.8531. 931,449 shares were traded during trading, an increase of 337% from the average session volume of 213,025 shares. The stock had previously closed at $1.00. | Defense World | 2026-02-19 03:31:06 |
| NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS | CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2026-02-18 09:05:00 |
| NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition | Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2026-02-09 09:20:00 |
| NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease | Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2026-01-21 08:30:00 |
| World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB | Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2026-01-08 08:45:00 |
| NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages | Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) have earned an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two | Defense World | 2025-12-31 01:26:59 |
| NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study | Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2025-12-22 09:17:00 |
| NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 | CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. | PRNewsWire | 2025-12-04 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-18 | 2026-02-18 | View Filing |
| 6-K | 2026-02-13 | 2026-02-13 | View Filing |
| 6-K | 2026-02-09 | 2026-02-09 | View Filing |
| F-3 | 2026-01-29 | 2026-01-29 | View Filing |
| 6-K | 2026-01-06 | 2026-01-06 | View Filing |
| 6-K | 2025-12-22 | 2025-12-22 | View Filing |
| 6-K | 2025-12-08 | 2025-12-08 | View Filing |
| 6-K | 2025-12-04 | 2025-12-04 | View Filing |
| 424B3 | 2025-11-26 | 2025-11-26 | View Filing |
| EFFECT | 2025-11-25 | 2025-11-26 | View Filing |
| 6-K | 2025-11-24 | 2025-11-24 | View Filing |
| 6-K | 2025-11-21 | 2025-11-21 | View Filing |
| F-3 | 2025-10-28 | 2025-10-28 | View Filing |
| 6-K | 2025-10-06 | 2025-10-06 | View Filing |
| 6-K | 2025-09-25 | 2025-09-25 | View Filing |
| 6-K | 2025-09-10 | 2025-09-10 | View Filing |
| 6-K | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-09-02 | 2025-09-02 | View Filing |
| 6-K | 2025-08-21 | 2025-08-21 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| EFFECT | 2025-08-19 | 2025-08-19 | View Filing |
| EFFECT | 2025-08-19 | 2025-08-19 | View Filing |
| S-8 | 2025-08-15 | 2025-08-15 | View Filing |
| POS AM | 2025-08-15 | 2025-08-15 | View Filing |
| POS AM | 2025-08-15 | 2025-08-15 | View Filing |
| 424B5 | 2025-08-08 | 2025-08-08 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| 6-K | 2025-07-10 | 2025-07-10 | View Filing |
| 6-K | 2025-06-26 | 2025-06-26 | View Filing |
| 6-K | 2025-05-07 | 2025-05-07 | View Filing |
| 6-K | 2025-04-24 | 2025-04-24 | View Filing |
| EFFECT | 2025-04-17 | 2025-04-17 | View Filing |
| EFFECT | 2025-04-17 | 2025-04-17 | View Filing |
| POS AM | 2025-04-11 | 2025-04-11 | View Filing |
| POS AM | 2025-04-11 | 2025-04-11 | View Filing |
| 6-K | 2025-04-07 | 2025-04-07 | View Filing |
| 20-F | 2025-04-07 | 2025-04-07 | View Filing |
| 6-K | 2025-03-27 | 2025-03-27 | View Filing |
| 6-K | 2025-03-19 | 2025-03-19 | View Filing |
| 424B5 | 2025-02-21 | 2025-02-21 | View Filing |
| 6-K | 2025-02-19 | 2025-02-19 | View Filing |
| 424B3 | 2025-01-17 | 2025-01-17 | View Filing |
| EFFECT | 2025-01-17 | 2025-01-17 | View Filing |
| 6-K | 2025-01-06 | 2025-01-06 | View Filing |
| F-3 | 2024-12-26 | 2024-12-26 | View Filing |
| 6-K | 2024-12-23 | 2024-12-23 | View Filing |
| 6-K | 2024-12-18 | 2024-12-18 | View Filing |
| 6-K | 2024-12-17 | 2024-12-17 | View Filing |
| EFFECT | 2024-12-13 | 2024-12-13 | View Filing |
| 424B3 | 2024-12-12 | 2024-12-12 | View Filing |
| D | 2024-12-12 | 2024-12-12 | View Filing |
| 6-K | 2024-12-11 | 2024-12-11 | View Filing |
| SC 13G | 2024-12-09 | 2024-12-09 | View Filing |
| F-3 | 2024-12-06 | 2024-12-06 | View Filing |
| 6-K | 2024-12-04 | 2024-12-04 | View Filing |
| 6-K | 2024-12-02 | 2024-12-02 | View Filing |
| EFFECT | 2024-11-25 | 2024-11-25 | View Filing |
| 424B3 | 2024-11-22 | 2024-11-22 | View Filing |
| F-1 | 2024-11-19 | 2024-11-19 | View Filing |
| 6-K | 2024-10-31 | 2024-10-31 | View Filing |
| 6-K | 2024-10-30 | 2024-10-30 | View Filing |
| 6-K | 2024-10-28 | 2024-10-28 | View Filing |
| 6-K | 2024-10-24 | 2024-10-24 | View Filing |
| 6-K | 2024-10-15 | 2024-10-15 | View Filing |
| 6-K | 2024-10-09 | 2024-10-09 | View Filing |
| EFFECT | 2024-10-07 | 2024-10-07 | View Filing |
| POS AM | 2024-10-01 | 2024-10-01 | View Filing |
| 6-K | 2024-09-30 | 2024-09-30 | View Filing |
| 6-K | 2024-09-24 | 2024-09-24 | View Filing |
| 6-K | 2024-09-16 | 2024-09-16 | View Filing |
| 6-K | 2024-09-09 | 2024-09-09 | View Filing |
| 6-K | 2024-08-30 | 2024-08-30 | View Filing |
| 6-K | 2024-08-28 | 2024-08-28 | View Filing |
| 6-K | 2024-08-26 | 2024-08-26 | View Filing |
| 6-K | 2024-08-16 | 2024-08-16 | View Filing |
| 424B5 | 2024-08-16 | 2024-08-16 | View Filing |
| 6-K | 2024-08-07 | 2024-08-07 | View Filing |
| 6-K | 2024-08-01 | 2024-08-01 | View Filing |
| 6-K | 2024-07-09 | 2024-07-09 | View Filing |
| 6-K | 2024-07-03 | 2024-07-03 | View Filing |
| 6-K | 2024-07-01 | 2024-07-01 | View Filing |
| 424B3 | 2024-06-27 | 2024-06-27 | View Filing |
| 424B3 | 2024-06-27 | 2024-06-27 | View Filing |
| 6-K | 2024-06-27 | 2024-06-27 | View Filing |
| 6-K | 2024-06-24 | 2024-06-24 | View Filing |
| 6-K | 2024-06-21 | 2024-06-21 | View Filing |
| 424B3 | 2024-06-17 | 2024-06-17 | View Filing |
| 424B3 | 2024-06-17 | 2024-06-17 | View Filing |
| 6-K | 2024-06-17 | 2024-06-17 | View Filing |
| 6-K | 2024-05-28 | 2024-05-28 | View Filing |
| 6-K | 2024-05-23 | 2024-05-23 | View Filing |
| EFFECT | 2024-05-23 | 2024-05-23 | View Filing |
| 424B3 | 2024-05-22 | 2024-05-22 | View Filing |
| F-1/A | 2024-05-20 | 2024-05-20 | View Filing |
| 6-K | 2024-05-20 | 2024-05-20 | View Filing |
| 6-K | 2024-05-14 | 2024-05-14 | View Filing |
| F-1 | 2024-05-10 | 2024-05-10 | View Filing |
| 6-K | 2024-05-07 | 2024-05-07 | View Filing |
| D | 2024-04-25 | 2024-04-25 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Hull Moving Average Strategy | 25.78% | 0.98 | 38 | 0.57 | 0.42 | 29.63 |
| Heikin Ashi Strategy | 23.60% | 1.17 | 11 | 0.52 | 0.61 | 27.46 |
| Williams PercentR Strategy | 16.38% | 1 | 20 | 0.78 | 0 | 20.24 |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |